{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:41:23Z","timestamp":1760146883958,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by mutations in the TSC1 and TSC2 genes, leading to the dysregulation of the mammalian target of rapamycin (mTOR) pathway. This dysregulation results in the development of benign tumors across multiple organ systems and poses significant neurodevelopmental challenges. The clinical manifestations of TSC vary widely and include subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), facial angiofibromas (FAs), and neuropsychiatric conditions such as autism spectrum disorder (ASD). mTOR inhibitors, notably everolimus, have become central to TSC management, with documented efficacy in reducing the sizes of SEGAs and AMLs and showing promise in addressing additional TSC-related symptoms. Case Presentation: We report the case of an 11-year-old male diagnosed with TSC, presenting with hallmark features including hypopigmented macules, early-onset infantile spasms, SEGA, and AMLs. Initial interventions included adrenocorticotropic hormone (ACTH) therapy and sodium valproate for seizure management and a minimally invasive keyhole craniotomy for SEGA reduction. At age 12, oral everolimus therapy was introduced to address both SEGA recurrence risk and ASD-related social deficits. Over the course of 24 weeks, a reduction in the size and erythema of the patient\u2019s FAs was observed, alongside improvements in social engagement, suggesting potential added benefits of systemic mTOR inhibition beyond tumor control. Results: Treatment with everolimus over a 24-month period led to significant reductions in both FA and AML size, as well as measurable improvements in ASD-associated behaviors. Therapeutic drug monitoring maintained serum levels within the effective range, minimizing adverse effects and underscoring the tolerability and feasibility of long-term everolimus administration. Conclusions: This case underscores the efficacy of oral everolimus in reducing FA size in a pediatric TSC patient, with broader therapeutic benefits that support the potential of mTOR inhibition as a multi-targeted strategy for TSC management. Further studies are needed to explore the full range of applications and long-term impact of mTOR inhibitors in TSC care.<\/jats:p>","DOI":"10.3390\/diseases12120334","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T04:07:40Z","timestamp":1734667660000},"page":"334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Therapeutic Potential of Oral Everolimus for Facial Angiofibromas in Pediatric Tuberous Sclerosis Complex: A Case-Based Analysis of Efficacy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-0460","authenticated-orcid":false,"given":"George","family":"Imataka","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunio","family":"Yui","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Igawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigemi","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dokkyo Medical University, Tochigi 321-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","article-title":"Subependymal giant cell astrocytoma in tuberous sclerosis complex: Guidelines for management","volume":"49","author":"Roth","year":"2013","journal-title":"Pediatr. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy of everolimus for SEGAs in TSC: EXIST-1 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"ref_5","first-page":"293","article-title":"Rapamycin for TSC-related disorders: Mechanisms and evidence","volume":"59","author":"Ehninger","year":"2008","journal-title":"Brain Res. Rev."},{"key":"ref_6","first-page":"1271","article-title":"Everolimus for renal AML in TSC","volume":"33","author":"Davies","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for AML in TSC or sporadic LAM: EXIST-2 trial","volume":"31","author":"Bissler","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_8","first-page":"2521","article-title":"Long-term everolimus in TSC-associated AML","volume":"29","author":"Kingswood","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_9","first-page":"39","article-title":"Efficacy of sirolimus gel for FAs in TSC","volume":"153","author":"Tanaka","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_10","first-page":"91","article-title":"TSC and everolimus treatment guidelines","volume":"163C","author":"Krueger","year":"2013","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"ref_11","first-page":"339","article-title":"TSC-mTOR pathway and regulation of cell growth","volume":"9","author":"Huang","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_12","unstructured":"Wang, J., Peng, T., Yin, Q., Li, X., Zhang, C., Wang, Y., Zhang, X., Feng, Z., and Li, S. (2015). Everolimus reduces autism-like behaviors in TSC2 mice. Sci. Rep., 5."},{"key":"ref_13","first-page":"2070619","article-title":"Improvement in social cognition by everolimus in TSC","volume":"2019","author":"Yui","year":"2019","journal-title":"Case Rep. Pediatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","article-title":"Efficacy and safety of topical rapamycin in TSC: TREATMENT trial","volume":"154","author":"Koenig","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_15","first-page":"225","article-title":"Guidelines for rapamycin gel in TSC","volume":"15","author":"Pass","year":"2021","journal-title":"Dermatol. Pract. Res."},{"key":"ref_16","first-page":"187","article-title":"Topical corticosteroids in clinical practice","volume":"74","author":"Devaraj","year":"2019","journal-title":"Med. J. Malaysia."},{"key":"ref_17","first-page":"741","article-title":"Exploring sirolimus applications in TSC dermatology","volume":"184","author":"Hart","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_18","first-page":"13030","article-title":"Everolimus and dermatologic improvements in TSC","volume":"24","author":"Koenig","year":"2018","journal-title":"Dermatol. Online J."},{"key":"ref_19","first-page":"128","article-title":"Safety and efficacy of mTOR inhibitors in children","volume":"25","author":"Segal","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00381-023-06200-y","article-title":"An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients","volume":"40","author":"Liu","year":"2024","journal-title":"Child\u2019s Nervous System."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lin, Y.T., Yu, C.L., and Chi, C.C. (2022). Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10040826"},{"key":"ref_22","first-page":"1125","article-title":"Dual inhibition of mTORC1\/mTORC2 in TSC","volume":"29","author":"Rojas","year":"2020","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_23","first-page":"203","article-title":"Current trends in mTOR inhibition for TSC","volume":"101","author":"Medley","year":"2022","journal-title":"Clin. Genet."},{"key":"ref_24","first-page":"737","article-title":"Review on mTOR pathway in TSC","volume":"32","author":"Lendvai","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_25","first-page":"1035","article-title":"Novel treatments targeting mTOR in TSC","volume":"16","author":"Hussain","year":"2020","journal-title":"Future Oncol."},{"key":"ref_26","first-page":"1455","article-title":"Pharmacological advances in TSC management","volume":"18","author":"Sabatini","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","first-page":"636","article-title":"TSC pharmacology and management","volume":"31","author":"Davies","year":"2019","journal-title":"Curr. Opin. Pediatr."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/12\/334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:56:11Z","timestamp":1760115371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/12\/334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["diseases12120334"],"URL":"https:\/\/doi.org\/10.3390\/diseases12120334","relation":{},"ISSN":["2079-9721"],"issn-type":[{"type":"electronic","value":"2079-9721"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}